Hypromeloza-p [Hypromellose]
Unimed Pharma
1195 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
The protector of the corneal epithelium, has a lubricating and softening effect, has a high viscosity, increases the duration of contact of the solution with the cornea. The refractive index of the solution is similar to natural tears. Restores, stabilizes and reproduces the optical characteristics of the tear film.
Subjective and objective improvement of the condition (epithelization, reduction of hyperemia, lesions) usually occurs within 3-5 days, pronounced improvement or complete recovery - within 2-3 weeks.
Pharmacodynamics
It has a protective effect on the cornea with reduced secretion of tear fluid, increases the duration of the action of eye drops and protects the cornea from their irritant action.
Indications
- Erosions and trophic changes of the cornea.
- Microtraumas of the corneal epithelium.
- Bullous dystrophic changes of the cornea.
- Keratopathy.
- Ectropion.
- Eyelid deformity, lagophthalmos.
- Condition after blepharoplasty, thermal corneal burns and conjunctiva.
- Keratoplasty.
- Keratectomy.
- Replacement therapy with reduced secretion of tear fluid.
- Dry Eye Syndrome (Sjogren syndrome).
- Xerosis.
- Keratosis (combination therapy).
- Prolonged action or reduction of the irritating effect of other eye drops.
Composition
Transparent, colorless, slightly viscous, with insignificant opalescence, solution.
Active substance
- Hypromelloses 50 mg.
Excipients
- Dexpanthenol.
- Sodium chloride.
- Disodium edetate dihydrate.
- Benzalkoniya chloride.
- Purified water to 10 ml.
No customer reviews for the moment.
Dosage and Administration
1-2 drops are instilled into the conjunctival sac in the lower conjunctival sac 4-8 times a day; if necessary, you can enter every hour.
The course of treatment is at least 2-3 weeks.
Adverse reactions
Allergic reactions, unpleasant feeling of gluing of the eyelids (due to the high viscosity of the solution).
Contraindications
Hypersensitivity.C caution. acute phase of corneal and conjunctival burns (until complete removal of toxic substances and necrotic tissue).
Drug interactions
Not compatible with eye drops containing metal salts.
Special instructions
Do not exceed therapeutic doses, do not use for a long time.
It is not recommended to use drops in the acute stage of chemical burn of the cornea and conjunctiva until complete removal of the toxic substance.
Use only when wearing contact lenses.
- Brand name: Hypromeloza-p
- Active ingredient: Hypromellose
Studies and clinical trials of Hypromellose (Click to expand)
- A framework to investigate drug release variability arising from hypromellose viscosity specifications in controlled release matrix tablets
- Swelling and erosion properties of hydroxypropylmethylcellulose (Hypromellose) matrices—influence of agitation rate and dissolution medium composition
- Initial studies of water granulation of eight grades of hypromellose (HPMC)
- Influence of ethanol on aspirin release from hypromellose matrices
- Performance qualification of a new hypromellose capsule: Part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus®, Quali-V® and gelatin capsules
- The butterfly effect: A physical phenomenon of hypromellose matrices during dissolution and the factors affecting its occurrence
- The assay of benzalkonium chloride in pilocarpine, hypromellose and polyvinyl alcohol ophthalmic drops by second-order derivative ultraviolet spectrophotometry
- Effect of ionic strength and pH of dissolution media on theophylline release from hypromellose matrix tablets—Apparatus USP III, simulated fasted and fed conditions
- A randomised controlled study of the efficacy of hypromellose and Lacri-Lube combination versus polyethylene/Cling wrap to prevent corneal epithelial breakdown in the semiconscious intensive care patient
- Study of dissolution hydrodynamic conditions versus drug release from hypromellose matrices: The influence of agitation sequence
- Dissolution parameters for sodium diclofenac-containing hypromellose matrix tablet
- In Vitroandin VivoPharmacoscintigraphic Evaluation of Ibuprofen Hypromellose and Gelatin Capsules
- Investigation of the Effects of Hydroalcoholic Solutions on Textural and Rheological Properties of Various Controlled Release Grades of Hypromellose
- Bio-Dis and the Paddle Dissolution Apparatuses Applied to the Release Characterization of Ketoprofen from Hypromellose Matrices
- Magnetic resonance imaging study of the transport phenomena of solvent into the gel layer of hypromellose matrices containing tetracycline hydrochloride
- Hypromellose films for the delivery of growth factors for wound healing
- Reviewing the use of ethylcellulose, methylcellulose and hypromellose in microencapsulation. Part 3: Applications for microcapsules
- Reviewing the use of ethylcellulose, methylcellulose and hypromellose in microencapsulation. Part 2: Techniques used to make microcapsules
- Reviewing the use of ethylcellulose, methylcellulose and hypromellose in microencapsulation. Part 1: materials used to formulate microcapsules
- A scintigraphic investigation of the disintegration behaviour of capsules in fasting subjects: A comparison of hypromellose capsules containing carrageenan as a gelling agent and standard gelatin capsules
- Performance qualification of a new hypromellose capsule: Part II. Disintegration and dissolution comparison between two types of hypromellose capsules
- The disintegration behaviour of capsules in fed subjects: A comparison of hypromellose (carrageenan) capsules and standard gelatin capsules
- Absolute molecular weight determination of hypromellose acetate succinate by size exclusion chromatography: Use of a multi angle laser light scattering detector and a mixed solvent
- EFFICACY AND SAFETY OF HYPROMELLOSE IN OCULAR IMPLANT SURGERY
8 other products in the same category:
arrow_upward